Atriva Therapeutics is starting a phase 2 trial of its MEK inhibitor ATR-002 in patients with coronavirus infections, saying the drug could help prevent patients progressing to
Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl
